By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk

We already know that the radical drug pricing plan unveiled last week by House Speaker Nancy Pelosi is the wrong approach for patients, the U.S. health care system, and American innovation. But what...
Read More
ICYMI: Fighting for a cure to ALS

Yesterday at The Atlantic Festival, I had the chance to speak with Amy, a biopharmaceutical researcher focused on amyotrophic lateral sclerosis (ALS). As a young girl, Amy’s father inspired her to...
Read More
Four reasons why the radical Pelosi Plan is the wrong approach

Speaker of the House Nancy Pelosi recently unveiled a radical plan that would restrict and fundamentally change how patients access medicines in the United States. It would threaten our country’s...
Read More
IP Explained: Four things to know about the Bayh-Dole Act

Thanks in large part to strong intellectual property protections – including policies that incentivize public and private investments in research and development (R&D) – the United States is the ...
Read More
Hospitals make 9 times more than physicians’ offices on provider-administered medicines

A new study, conducted by the Partnership for Health Analytic Research (PHAR), found that hospitals retained 91% of the total profit on physician-administered medicines in the commercial market that...
Read More
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More